Influence of male age on the outcome of conventional IVF-ET / 中华男科学杂志

<p><b>OBJECTIVE</b>To study the influence of male age on the outcome of conventional IVF-ET.</p><p><b>METHODS</b>Based on male age, 170 couples undergoing conventional IVF-ET were divided into three groups: <35 yr (n = 60), 35 -39 yr (n = 77) and > or = 40 yr (n = 33). We observed the rates of fertilization, cleavage, good quality embryo, implantation, clinical pregnancy and abortion in different groups.</p><p><b>RESULTS</b>There were no significant differences among the three groups in semen volume ([3.10 +/- 1.22] ml vs [2.84 +/- 1.05] ml vs [2.80 +/- 0.79] ml), sperm concentration ([54.23 +/- 26.07] x 10(6)/ml vs [60.27 +/- 24.80] x 10(6)/ml vs [60.21 +/- 27.42] x 10(6)/ml) and sperm viability ([53.93 +/- 13.25]% vs [56.10 +/- 16.58]% vs [51.82 +/- 15.45]%) (P>0.05). The men of the > or = 40 yr group showed a significantly lower percentage of grade a + b sperm ([40.97 +/- 11.91]%) than those of the <35 and 35 - 39 yr groups ([48.47 +/- 11.78]% and [46.84 +/- 13.51]%) (P<0.05), and morphologically normal sperm ([11.76 +/- 5.97]%) than those of the <35 yr group ([15.25 +/- 6.94]% (P<0.05). The rates of fertilization, cleavage, good quality embryo, implantation, clinical pregnancy were 81.52%, 82.61%, 52.33%, 18.06% and 33.33% in the > or = 40 yr group, with no significant differences from those of the <35 yr group (83.18%, 82.68%, 56.99%, 22.40% and 40.00%) and the 35 - 39 yr group (78.78%, 80.66%, 55.01%, 21.74% and 38.96%) (P>0.05), while the abortion rate was markedly increased in the > or = 40 yr group as compared with the <35 yr group (36.36% vs 8.33%, P>0.05).</p><p><b>CONCLUSION</b>Increasing male age is related with decreasing percentages of progressively motile sperm and morphologically normal sperm, but not obviously with the rates of fertilization, good quality embryo, implantation, pregnancy and abortion.</p>

Effects of males' age on sperm apoptosis and DNA integrity / 中华男科学杂志

<p><b>OBJECTIVE</b>To explore the correlation of males'age with sperm apoptosis, sperm DNA integrity and other seminal parameters.</p><p><b>METHODS</b>We collected 104 semen samples and divided them into three groups according to the males' age: <35 yr (n = 43), 35 -39 yr (n = 31), and > or = 40 yr (n = 30). Based on the WHO Laboratory Manual (4th ed), we detected the seminal parameters, calculated the percentage of apoptotic sperm by flow cytometry (FCM), determined sperm DNA integrity by Acridine orange staining, and compared the results among the three groups.</p><p><b>RESULTS</b>There were no statistically significant differences among the < 35 yr, 35 -39 yr and > or = 40 yr groups in semen volume ([2.87 +/- 0.89] ml vs [2.98 +/- 1.09] ml vs [2.65 +/- 0.95] ml), sperm concentration ([60.40 +/- 25.43] x 10(6)/ml vs [69.74 +/- 28.33] x 10(6)/ml vs [55.97 +/- 27.22] x 10(6)/ml) (P>0.05). The percentage of progressively motile sperm was significantly lower in the > or = 40 yr ([39.00 +/- 8.35 %) than in the <35 and 35 -39 yr groups ([48.73 +/- 9.89]% and [45.65 +/- 10.55]%) (P<.0.1), and so was the percentage of morphologically normal sperm in the > or = 40 yr than in the < 35 yr group ([11.11 +/- 8.26]% vs [16.43 +/- 8.75 ]%, P<0.01). The percentage of apoptotic sperm was markedly higher in the > or = 40 yr than in the <35 yr group ([11.82 +/- 5.77]% vs [7.04 +/- 3.50]%, P<0.01), while the sperm DNA integrity significantly reduced in the > or = 40 yr group ([75.52 +/- 10.60]%) as compared with the <35 yr ([86.55 +/- 5.60])% and 35 -39 yr group ( [81.39 +/- 8.94]%) (P<0.01). The males' age was correlated positively with the rate of sperm apoptosis (P<0.01), and negatively with sperm DNA integrity and the percentage of progressively motile sperm (P<0.01).</p><p><b>CONCLUSION</b>The advance in males' age increases sperm apoptosis and reduces sperm progressive motility, normal morphology and DNA integrity.</p>

Expression of SKP2 protein in lung carcinoma and its implication for prognosis / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the characteristics of SKP2 protein expression in lung carcinoma tissues and its implication for prognosis.</p><p><b>METHODS</b>The expression of SKP2 protein was detected in 89 NSCLC, 13 SCLC, 5 benign lung neoplasms, 5 normal bronchus and lung tissues by tissue chip and immunohistochemical techniques.</p><p><b>RESULTS</b>The positive rate of SKP2 staining was (23.52 +/-13.57)% in NSCLC tissues and (53.85 +/- 12.26)% in SCLC tissues, significantly higher than (2.91 +/- 1.27)% in benign lung neoplasms and normal bronchus and lung tissues. Its expression was highest in SCLC tissues and lowest in benign lung tissues, with a significant difference between them (P <0.01). The expressive level of SKP2 protein in lung carcinoma tissues was closely related to cell differentiation and lymph node metastasis, but not to age, sex, smoking history, tumor site and size, and TNM staging, etc. The survival analysis revealed that the 5-year survival rate of lung carcinoma patients was much lower in SKP2 protein positive expression group than that in negative expression group (P < 0.01).</p><p><b>CONCLUSION</b>The positive expression of SKP2 protein is higher in lung carcinoma than in benign or normal lung tissues, in particular, much higher in SCLC tissue. Moreover, it may be an independent factor to exert negative influence on prognosis of patients with lung carcinoma.</p>

Sequence analysis of the connexin 26 genes from a deafness family with A1555G mutation in Huaiyin / 中华耳鼻咽喉头颈外科杂志

<p><b>OBJECTIVE</b>To ascertain whether connexin 26 (Cx26) gene was a nuclear modifier gene in an extensive family with matrilineal nonsyndromic deafness associated with A1555G mutation in Huaiyin, China.</p><p><b>METHODS</b>Following PCR-restriction fragment length polymorphism (PCR-RFLP) with ApaI restriction enzyme, Cx26 genes from 26 cases, with A1555G mitochondrial mutations in this family, and 62 controls (including 2 patrilineal relatives, 10 spouse controls and 50 unrelated controls), were sequenced.</p><p><b>RESULTS</b>Compared with the reference sequence of Cx26 gene, totally four kinds of nucleotide changes,79G -->A, 109G-->A, 341G-->A and 235delC, were detected in a heterozygous form. However, the former three were previously reported polymorphisms, and only the 235delC was a previously described recessive mutation associated with most autosomal nonsyndromic sensorineural hearing loss in Japan and China. Further study showed that the heterozygous 235delC mutation existed in both one individual with mild hearing loss and two individuals with normal hearing. Clinical characterization showed that 235delC mutation did not seem to modify the deafness phenotype due to the A1555G mutation. Moreover, this 235delC mutation was deduced to derive from a married-in control. Finally, there were no co-segregation between the phenotypes of hearing loss and the genotypes for Cx26 genes based on the four kinds of nucleotide changes.</p><p><b>CONCLUSIONS</b>The heterozygous 235delC mutation of the Cx26 gene may not modulate the severity of hearing loss associated with A1555G mutation and Cx26 gene is unlikely to be a modifier gene for hearing loss due to A1555G mitochondrial mutation in this Chinese family.</p>

Sequence analysis of the mitochondrial genome from a large family with maternally inherited nonsyndromic deafness / 中华医学遗传学杂志

<p><b>OBJECTIVE</b>To ascertain whether other variations coexist with 1555(A--> G) mutation in the mitochondrial DNA and may aggravate the severity of hearing loss or increase the penetrance of 1555(A--> G) mutation in a large family with maternally inherited nonsyndromic deafness in Huaiyin, Jiangsu province.</p><p><b>METHODS</b>PCR-restriction fragment length polymorphism (PCR-RFLP) was used to screen both the nt1555 and the nt7445 of the mitochondrial DNA from 27 maternal members in the core family; and then the mitochondrial genomes from two maternal members, and the 12S rRNA genes MTRNR1 and tRNA-Ser(UCN) gene MTTS1 from the others, were amplified by PCR-RFLP and were sequenced.</p><p><b>RESULTS</b>1555(A--> G) mutation in the mitochondrial DNA was reverified to be one of the major factors which cause maternally inherited nonsyndromic deafness and the cosegregation of 955-960(insC) and 1555(A--> G) was present in this family. Moreover, 7449 (insG), a novel homoplasmic mutation in the tRNA-Ser(UCN) gene, was found to co-exist with 1555(A--> G) mutation in two maternal members.</p><p><b>CONCLUSION</b>The cosegregation of 955-960(insC) and 1555(A--> G) implies that 955-960(insC) may synergistically cause hearing loss in the presence of an 1555(A--> G) mutation, serving as an aggravating factor to enhance the sensitivity to aminoglycosides, and may sometimes increase the penetrance of 1555(A--> G) mutation.</p>

Clinical applicatio of VAMTS in lung cancer patients / 肿瘤研究与临床

Objective To evaluate the clinical application of VAMTS in lung cancer patients.Meth- ods Between May 2004 and June 2005,30 patients with lung cancer applied VAMTS.The minimalthoracto- my from 8 to 10 cm was made at fourth or fifth intercostal space and lobectomy was undergone for convertion- al or dedicated endoscopic instruments.Some mediastinum lymphnode(MLN)resection were performed.Re- suits Operative time from 50 to 210 minutes and average 123 minutes.The intraoperative blood loss is less, and without blood transfusion.The average drawing duct time is 3.9 days.No death caused by operation and postoperative syndromes.Conclusion VAMTS wounds much less,operative scale lumination is better,opera- tive time shorter,blood loss less,and recover more quickly.The hospitalization time is shorter.The VAMTS with MLNR is regarded as an implement of lung cancer remedy,fits to stageⅠ-Ⅱ,diameter